Picture of Mainz Biomed NV logo

MYNZ Mainz Biomed NV Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-26.01%
3m-58.37%
6m-67.31%
1yr-92.08%
Volume Change (%)
10d/3m+92.02%
Price vs... (%)
52w High-91.04%
50d MA-39.59%
200d MA-67.88%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-430.81%
Return on Equity-303.2%
Operating Margin-2969.29%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Mainz Biomed NV EPS forecast chart

Profile Summary

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    March 8th, 2021
    Public Since
    November 4th, 2021
    No. of Employees
    65
    Sector
    Healthcare Providers & Services
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    21,886,575

    MYNZ Share Price Performance

    Upcoming Events for MYNZ

    Q2 2024 Mainz Biomed NV Earnings Release

    Q3 2024 Mainz Biomed NV Earnings Release

    Similar to MYNZ

    Picture of 23andMe Holding Co. logo

    23andMe Holding Co.

    us flag iconNASDAQ Capital Market

    Picture of ADVANCED BIOMED logo

    ADVANCED BIOMED

    us flag iconNASDAQ Capital Market

    Picture of Akanda logo

    Akanda

    us flag iconNASDAQ Capital Market

    Picture of Assure Holdings logo

    Assure Holdings

    us flag iconNASDAQ Capital Market

    Picture of Astrana Health logo

    Astrana Health

    us flag iconNASDAQ Capital Market

    FAQ